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Persistent (not intermittent) nasal carriage of Staphylococcus
aureus is the determinant of CPD-related infections.
Background. We investigated the impact of staphylococ-
cal carriage among patients on continuous peritoneal dialysis
(CPD) in a university hospital.
Methods. Patients were screened for Staphylococcus aureus
carriage and categorized as persistent, intermittent, or non–
S. aureus nasal carriers. Patients were subsequently recultured
every 12 weeks for S. aureus and coagulase negative staphylo-
coccal (CoNS) carriage, and followed-up for CPD-related in-
fections and antibiotic resistance.
Results. Fifty-two patients were included: 20 peristent, 10
intermittent, and 22 non–S. aureus carriers. Only persistent
S. aureus carriage was significantly associated with an increased
risk for all CPD-related infections [incidence rate ratio (IRR)
3.52 (95% CI: 2.56–4.85)], exit site infections [IRR 5.59 (95%
CI: 3.50–8.92)], and peritonitis [IRR 2.19 (95% CI: 1.39–3.45)],
as well as increased antibiotic use [IRR 3.43 (95% CI: 2.50–
4.72)], including vancomycin [IRR 2.15 (95%: 2.13–2.16)]. No
vancomycin-resistant S. aureus strains were detected. However,
eight (2%) out of 407 CoNS strains isolated were vancomycin in-
termediately susceptible. In all five patients (four persistent and
one intermittent carriers) concerned, this was significantly re-
lated to a higher antibiotic (including vancomycin) usage [IRR
2.65 (95% CI: 1.82–3.84)].
Conclusion. Persistent—but not intermittent—S. aureus
nasal carriage is the major determinant of CPD-related infec-
tions, and is associated with a significantly higher consumption
of antibiotics, including vancomycin. The highly diverse pop-
ulation of CoNS appears to be the prime reservoir of staphy-
lococcal vancomycin resistance. Accurate determination of the
S. aureus nasal carriage state of CPD patients is essential to
better target intervention strategies to prevent CPD-related
infections.
Continuous peritoneal dialysis (CPD) is a commonly
used technique in patients with chronic renal failure.
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CPD–catheter-related infections (including peritonitis,
exit site, and tunnel infections) are frequently encoun-
tered complications, and result in significant morbid-
ity, mortality, and costs. The majority of these CPD-
related infections are caused by Staphylococcus aureus
and coagulase-negative staphylococci (CoNS).
S. aureus nasal carriage is a major risk factor for the
development of both community-acquired and nosoco-
mial infections, including CPD-related infections [1–5].
The anterior nares are the primary reservoir of S. au-
reus in humans [6–8]. The prevalence of S. aureus nasal
carriage has been estimated to be 50% in CPD patients
[9, 10], while cross-sectional surveys of healthy adult pop-
ulations have reported carriage rates between 20% and
55% [11–13]. From longitudinal studies, it is known that
S. aureus nasal carriage patterns differ between individ-
uals, and that 10% to 35% of individuals carry S. aureus
persistently (hence, called persistent S. aureus nasal car-
riers), 20% to 75% carry S. aureus intermittently (inter-
mittent carriers), and 5% to 50% never carry S. aureus
in their nose (noncarriers) [14–18]. However, data on the
true status of S. aureus carriage based on longitudinal
studies in patients on CPD are lacking.
Because S. aureus nasal carriage has been demon-
strated to be a major risk factor for S. aureus infections
in CPD patients [4, 19–25], several intervention studies
have adopted different strategies, including vaccination
[26, 27] and eradication of S. aureus using antimicro-
bial prophylaxis [10, 28–32]. These latter studies consis-
tently demonstrated a significant reduction in the inci-
dence of exit site infections, but not a consistent reduction
in the incidence of CPD-related peritonitis. Mupirocin is
the antibiotic agent commonly used in these interven-
tion studies. However, due to its popularity, resistance
to mupirocin is on the rise, compromising its usefulness
as an intervention tool in the prevention of S. aureus
infections [33]. Also, the cost-effectiveness of applying
mupirocin in the CPD setting has been questioned [34].
As a consequence, new intervention strategies need to be
developed.
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Table 1. Definitions of CPD-related infections
Peritonitis Peritonitis was diagnosed if at least two of the following three criteria were met: turbid peritoneal effluent with more
then 100 leukocytes/mm, of which more then 50% were neutrophilic granulocytes; abdominal pain or tenderness;
micro-organisms cultured from the peritoneal effluent.
Peritonitis was considered relapsing when it was caused by the same micro-organism as in the preceding episode,
within four weeks after discontinuing antimicrobial therapy.
Exit site infection Exit site infection (including tunnel and cuff infection) was defined as the presence of redness, pain, swelling, and/or
induration of the catheter exit site and/or of the overlying tissues, with or without purulent discharge or abscess
formation, together with a positive exit site culture.
Bacterial colonization Bacterial colonization was defined as micro-organisms present on the skin or mucosal surfaces without local signs or
symptoms of infection.
One of these strategies would be the targeting of pro-
phylactic antibiotics to high-risk patient groups only, in-
stead of the whole (CPD) population. In the case of
S. aureus nasal carriage, there still is no consensus on how
to define the S. aureus carrier states [35]. Precise deter-
mination of the S. aureus nasal carriage state is relevant
because earlier studies have shown the mean number of
colony forming units (CFU) of S. aureus isolated from the
anterior nares to be higher in persistent carriers than in
intermittent carriers [36, 37], resulting in more extensive
dispersal of the staphylococci in the environment [38] and
an increased risk of S. aureus infections [39–41].
Even less is known about the long-term molecular epi-
demiology of CoNS in CPD patients, with respect to
CPD-related infections caused by CoNS [42–44]. Further-
more, the long-term use of glycopeptides as first line an-
tibiotics in CPD-related infections has been related to the
development of glycopeptide resistance in staphylococci
(mainly CoNS). Since in our medical center vancomycin
treatment is part of the empiric antibiotic treatment of
CPD-related peritonitis, it could be questioned if short-
term vancomycin treatment is also a risk factor for the
development of glycopeptide resistance in staphylococci.
The main objectives of the present study, therefore,
were to provide more insight in the long-term molec-
ular epidemiology of S. aureus and coagulase negative
staphylococci (CoNS) carriage in CPD patients, and to
determine the value of differentiating between persis-
tent carriage, intermittent carriage, and noncarriage in
predicting the subsequent risk of CPD-related infections.
In addition, we determined the impact of empiric use of
vancomycin in CPD-related peritonitis on the risk of van-
comycin resistance in S. aureus and CoNS.
METHODS
Patients
The Erasmus University Medical Center Rotterdam
(Erasmus MC) is a 1250-bed tertiary care university hos-
pital with approximately 60 adult patients in its CPD
program. Table 1 summarizes the definitions used in the
present study for the different CPD-related infections.
The empiric antimicrobial therapy for CPD-related peri-
tonitis consisted of ceftazidime (loading dose of 500 mg/L
Table 2. Definitions of the different Staphylococcal aureus carrier
states
Noncarriers Noncarriers had zero out of six nasal
screening cultures positive for S. aureus.
Persistent carriers Persistent carriers had either six out of six
nasal screening cultures positive for S.
aureus, or four or five out of six nasal
screening cultures positive for S. aureus,
and at least one of the exit site cultures
positive for S. aureus at screening.
Genotyping showed all of these S. aureus
isolates to be identical.
Intermittent carriers Intermittent carriers had either less than four
out of six nasal screening cultures positive
for S. aureus, or four or five out of six nasal
screening cultures positive for S. aureus,
but no positive exit site culture or
genotypically nonidentical S. aureus
strains.
intraperitoneally, followed by 125 mg/L CPD dialysate
qid) plus vancomycin (2 g intraperitoneally once every
5–7 days). Antimicrobial therapy was adjusted according
to culture results, and given for at least two weeks. Exit
and tunnel infections were treated according to (routine)
culture results.
From January 1998 onward all current and new patients
on CPD were screened for S. aureus carriage with six con-
secutive nasal swab cultures (vestibulum nasi) taken at
one week intervals. S. aureus screening cultures of the
CPD catheter exit site were performed together with the
first and last nasal swab culture. Based on these culture
results, patients were divided into three categories (non-
carriers, intermittent carriers, and persistent carriers) ac-
cording to the definitions in Table 2.
After this initial screening period, nasal swab cultures,
cultures of CPD catheter exit site, and cultures of con-
tralateral (i.e., opposite to the catheter exit site) abdomi-
nal skin were taken every 12 weeks during follow-up vis-
its to identify colonization with S. aureus, CoNS species,
and/or other microorganisms. Cultures from other sites
(CPD dialysis fluid, wounds, blood, etc.) were performed
on indication only. Patients were followed-up for an over-
all period of four years until December 31, 2001, or until
the date of ending CPD treatment, whichever date came
earlier.
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From January 1, 1998 until December 31, 2001, data
on antibiotic use and (CPD-related) infections were col-
lected prospectively. Data on the molecular epidemiology
of CoNS and vancomycin resistance of the staphylococci
isolated were collected prospectively between January 1,
1998 and December 31, 2000. Data on antibiotic use and
(CPD-related) infections before January 1998 were col-
lected retrospectively by chart review.
Written informed consent was obtained from all pa-
tients included. This study was approved by our in-
stitutional Medical Ethics Review Committee (METC
165.585/1997/164).
Microbiological procedures
Phenotyping. Cultures from abdominal skin, catheter
exit site, nose (vestibulum nasi), blood, and CPD dialysis
fluid were performed according to standard procedures
[45]. Blood and CPD dialysis fluid were cultured using
the BACTEC 9240 system (Becton-Dickinson Diagnos-
tic Instrument Systems, Sparks, MD, USA). In the case
of CPD catheter removal, the tip was cultured in thiogly-
colate broth (Brewer modified).
MicroScan WalkAway-96 (Dade International, Inc.,
West Sacramento, CA, USA) and Vitek equipment
(bioMe´rieux Vitek, Hazelwood, MO, USA) were used
for the identification of microorganisms.
Swabs from nose, abdominal skin, and catheter exit site
were also cultured quantitatively on phenol-red mannitol
salt agar (PHMA) and in phenol red mannitol salt broth
(PHMB) for S. aureus according to a standard operating
procedure as described earlier [35, 37]. Culture results
were recorded as 0 (no S. aureus), 1 (S. aureus only from
PHMB), 2 [2–9 colony-forming units (CFU)], 3 (10–99
CFU), 4 (100–999 CFU), or 5 (≥1000 CFU). Identifica-
tion of S. aureus was based upon colony morphology on
the PHMA. Suspected colonies were cultured overnight
on Columbia blood agar plates (Becton-Dickinson B.V.,
Etten-Leur, The Netherlands). A catalase test and a latex
agglutination test (Staphaurex Plus, Murex, Dartford,
UK) were then performed on all staphylococcal isolates.
The ID32Staph test (bioMe´rieux, Lyon, France) was used
for further speciation of the CoNS. All staphylococcal iso-
lates were stored at −70◦C in glycerol-containing liquid
media.
Susceptibility testing. MicroScan WalkAway-96 and
Vitek equipment were also used for susceptibility test-
ing. Based on the NCCLS breakpoints, strains were cat-
egorized as resistant (R), intermediately sensitive (I), or
sensitive (S) to the antibiotic used [45–47]. Further MIC
determinations were done using E-test (AB Biodisk,
Solna, Sweden). Methicillin susceptibility of staphylo-
cocci was tested using the disc diffusion method.
Testing for vancomycin intermediate sensitivity (VISA
or VISE) or vancomycin resistance (VRSA or VRSE)
was done according to the method described by
Hiramatsu [48].
Genotyping (analysis of genetic relatedness). Pulsed-
field gel electrophoresis (PFGE) was performed based
on protocols as previously described [49]. Bacteria
were embedded in agarose plugs and treated with
lysostaphin (Sigma Aldrich, Munich, Germany), pro-
teinase K (Merck, Darmstadt, Germany), and the restric-
tion enzyme SmaI (Boehringer Mannheim, Mannheim,
Germany) prior to electrophoresis. The electrophoresis
program consisted of two blocks (10 hours 5–15 seconds
switch time followed by 10 hours 15–45 seconds switch
time), and was performed at 14◦C and 6 V/cm. Gels were
photographed after ethidium bromide staining, and band-
ing patterns were interpreted according to Tenover et al
[50].
Statistical procedures
Percentages were compared by the chi-square test
(Fisher exact test in case of 2 × 2 tables). To compare
the number of CPD-related infections and number of
antibiotic courses (including vancomycin) used during
follow-up between the different S. aureus carrier states,
Poisson regression analysis was employed. The influence
of potential prognostic factors on the incidence of CPD-
related infections and antibiotic usage was evaluated us-
ing Poisson regression, as well. Kaplan-Meier curves and
the log-rank test were used to evaluate differences in sur-
vival between the carrier states. We used a Cox propor-
tional hazards model to assess the effect of S. aureus nasal
carriage on mortality [51]. In these analyses, follow-up
ended either at death, date of renal transplantation, or
switch to intermittent hemodialysis, or end of the study
period. The non– or intermittent S. aureus nasal carrier
state was the reference category in all multiple regres-
sion models. Sex and age were included in all multiple
regression models to correct for potential confounding.
All statistical tests were two tailed and performed at
the 0.05 significance level. SAS statistical software (SAS
release 8.0; SAS Institute, Inc., Cary, NC, USA) was used
for Poisson regression analyses. All other statistical tests
were done using SPSS statistical software (SPSS version
12.0.1; SPSS, Inc., Chigago, IL, USA).
RESULTS
Demographics
Fifty-two patients were included in the study. Demo-
graphic data and prior history before start of the current
CPD episode are summarized in Table 3. Nearly twice as
many males as females participated (33 vs. 19).
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Table 3. Characteristics of the CPD Population at inclusion
Participants N
Males 33
Females 19
Age (median-range)
Males 50.0 (22.6–76.9)
Females 47.4 (19.4–70.4)
Cause of end stage renal disease N
Vascular disease 11
Diabetes mellitus 9
Glomerulonephritis 12
Urinary tract infections 10
TTP/HUS 2
Other 8
Previous kidney transplantations (s) N
No 38
1 8
2 4
3 2
Previous chronic intermittent hemodialysis N
No 36
Yes 16
Number of CPD catheters N
1st 42
2nd 8
3rd 1
4th 1
Diabetes mellitus N
No 37
Insulin dependent 10
Non-insulin dependent 5
Immunosuppressive medication N
No 47
Corticosteroids 3
Other 2
TTP, thrombotic thrombocytopenic purpura; HUS, hemolytic uremic
syndrome.
Table 4. S. aureus carriage patterns of CPD patients on screening
Nasal carriage N Non Intermittent Persistent Total
Male 13 (39%) 6 (18%) 14 (42%) 33 (100%)
Female 9 (47%) 4 (21%) 6 (32%) 19 (100%)
Total 22 (42%) 10 (19%) 20 (39%) 52 (100%)
S. aureus nasal carriage patterns
The distribution of the different S. aureus nasal carriage
groups, based on six weekly nasal swab cultures, is shown
in Table 4. There were 22 non–, 10 intermittent, and 20
persistent carriers. No difference in distribution between
males and females was found. Of the intermittent car-
riers, nine had only one nasal screening culture positive,
and one had three cultures positive but with two genotyp-
ically different strains and with negative exit site cultures.
Of the 20 persistent carriers, 13 had six out of six nasal
screening cultures positive. All of these 13 persons had
positive exit site cultures on at least one occasion, and all
strains isolated at screening were genotypically identical.
The other seven persistent carriers had four to five posi-
tive nasal screening cultures. In all of these patients, also,
exit site cultures were positive on at least one occasion,
and all strains isolated at screening were genotypically
identical.
Neither the cause of end-stage renal disease, a his-
tory of renal transplantation, a history of intermittent
hemodialysis, the presence of diabetes mellitus, nor the
use of corticosteroids or other immunosuppressive drugs
was significantly associated with S. aureus nasal carriage.
Follow-up
Total duration of follow-up was 2260 months, with
a median of 33.6 months (mean 43.5; range 1.6–204).
There was no difference in follow-up between the three
S. aureus nasal carriage groups (Table 5). Eighteen pa-
tients were still on CPD at the end of the study. In 34
patients, CPD therapy was stopped during the study (16
non–, 5 intermittent, and 13 persistent carriers; P = ns).
Fifteen patients received a kidney transplantation (5
non–, 3 intermittent, and 7 persistent carriers; P = ns).
In six patients, persisting or relapsing CPD peritonitis
necessitated removal of the CPD catheter (3 non– and 3
persistent carriers; P = ns): three were caused by Candida
albicans, one caused by C. albicans in combination with
Escherichia coli, and two caused by a perforation of the
colon.
Thirteen patients died during follow-up (8 non–, 2
intermittent, and 3 persistent carriers; P = ns). Three
patients died of CPD-related infections (1 caused by
Candida glabrata in combination with Enterobacter cloa-
cae, 1 caused by S. aureus, and 1 by a perforation of
the colon), two died of non–CPD-related infections (1
of fasciitis necroticans and 1 of pneumonia), and eight
died of noninfectious causes (atherosclerosis-related car-
diac and neurologic events). No CPD catheter had to be
removed because of (recurrent) exit site or tunnel infec-
tions. Persistent S. aureus nasal carriage was not associ-
ated with mortality [hazard ratio 1.276; 95% confidence
interval (CI): 0.658–2.475].
CPD-related infections
CPD-related infections occurred in all three carriage
groups, and are summarized in Table 5. As compared
to non– and intermittent carriers, persistent carriers pa-
tients had significantly higher incidences of all-cause
CPD-related infections [overall 0.13/month (P < 0.001),
exit site infections 0.09/month (P < 0.001), peritonitis
0.05/month (P = 0.019)] and S. aureus CPD-related in-
fections [overall 0.08/month (P < 0.001), exit site infec-
tions 0.07/month (P < 0.001), peritonitis 0.01/month (P =
0.026); Table 5]. Intermittent carriers behaved like non-
carriers as their incidence rates for CPD-related infec-
tions were similar (Table 5).
To calculate incidence rate ratios, the non– and inter-
mittent carrier groups were merged and compared with
the persistent carrier group. Age, sex, cause of end-stage
renal disease, history of intermittent hemodialysis, and
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Table 5. Infection incidence rates by S. aureus nasal carriage patterns
Non 95% Cl Intermittent 95% Cl Persistent 95% Cl Total 95% Cl P valuea IRRb,c 95% Cl
Follow-up (months at risk)
Mean 41.1 [28.1-54.1] 41.9 [15.3-68.6] 46.9 [26.0-67.7] 43.5 [33.3-53.7] 0.87
Total N 904 419 937 2260
Patients in follow-up N 22 10 20 52
CPD-related infections N
All 41 16 126 183
Exit site infections 17 8 81 106
Peritonitis 24 8 45 77
CPD-related infections
incidence (nr/
person months at risk)
All 0.05 [0.03-0.08] 0.04 [0.02-0.08] 0.13 [0.11-0.16] 0.08 [0.07-0.09] <0.001 3.52 [2.56-4.85]
Exit site infections 0.02 [0.01-0.04] 0.02 [0.01-0.05] 0.09 [0.07-0.11] 0.05 [0.04-0.06] <0.001 5.59 [3.50-8.92]
Peritonitis 0.03 [0.01-0.06] 0.02 [0.01-0.05] 0.05 [0.04-0.06] 0.03 [0.03-0.04] 0.019 2.19 [1.39-3.45]
S. aureus CPD-related
infections N
All 12 2 78 92
Exit site infections 9 2 65 76
Peritonitis 3 0 13 16
S. aureus CPD-related
infections incidence
(nr/person months at risk)
All 0.01 [0.01-0.03] 0.01 [0.00-0.02] 0.08 [0.07-0.10] 0.04 [0.03-0.05] <0.001 9.54 [5.25-17.33]
Exit site infections 0.01 [0.00-0.03] 0.01 [0.00-0.02] 0.07 [0.05-0.09] 0.03 [0.03-0.04] <0.001 10.75 [5.45-21.19]
Peritonitis 0.00 [0.00-0.02] 0 0.01 [0.01-0.02] 0.01 [0.00-0.01] 0.026 6.54 [1.83-23.31]
CoNS CPD-related
infections N
Peritonitis 5 3 18 26
CoNS CPD-related
infections incidence
(nr/person months at risk)
Peritonitis 0.01 [0.00-0.02] 0.01 [0.00-0.04] 0.02 [0.01-0.03] 0.01 [0.01-0.02] 0.018 3.37 [1.45-7.83]
aP value for the univariate comparison of incidence rates in non intermittent and persistent carriers using Poisson regression.
bIncidence rate ratio.
cComparing incidence rates in persistent carriers vs. in non- or intermittent carriers in a Poisson regression model adjusting for age, sex, and diabetes mellitus.
use of corticosteroids or other immunosuppressive drugs
were not associated with any category of CPD-related in-
fections in Poisson regressions analysis. Only persistent
S. aureus nasal carriage and the presence of diabetes mel-
litus were found to be significantly associated with CPD-
related infections. Persistent carriers had a more than
3-fold higher risk of all-cause CPD-related infections [in-
cidence rate ratio (IRR) 3.52 (95% CI: 2.56–4.85)] and
a more than 9-fold higher risk of S. aureus CPD infec-
tions [IRR 9.54 (95% CI: 5.25–17.33)] compared to non–
or intermittent carriers. The IRR for exit site infections,
S. aureus exit site infections, all peritonitis, S. aureus peri-
tonitis, and CoNS peritonitis were 5.59 (95% CI: 3.50–
8.92), 10.75 (95% CI: 5.45–21.19), 2.19 (95% CI: 1.39–
3.45), 6.54 (95% CI: 1.83–23.31), and 3.37 (95% CI: 1.45–
7.83), respectively (Table 5).
Patients with diabetes mellitus were at a 2-fold higher
risk of all-cause CPD-related infections [IRR 1.99 (95%
CI: 1.44–2.75)], S. aureus CPD infections [IRR 2.02 (95%
CI: 1.28–3.18)], all-cause exit site infections [IRR 2.33
(95% CI: 1.53–3.55)], and S. aureus exit site infections
[IRR 2.03 (95% CI: 1.23–3.34)]. However, no significant
association between diabetes mellitus and peritonitis was
found.
Antibiotic usage
Antibiotic usage also differed significantly between the
persistent carrier group and the combined non– or inter-
mittent carrier group: the number of antibiotic courses
per month for all infections was 0.13 (95% CI: 0.11–0.16)
in the persistent carrier group versus 0.04 (95% CI: 0.03–
0.07) in the non– or intermittent carrier group [IRR 3.43
(95% CI: 2.50–4.72); P < 0.001]. Also, vancomycin con-
sumption was higher in persistent carriers compared to
non– or intermittent carriers: 203 mg of vancomycin per
month (95% CI: 202–204) in persistent carriers versus
103 mg (95% CI: 102–104) in non– or intermittent car-
riers [IRR 2.15 (95%: 2.13–2.16); P < 0.001]. Diabetes
mellitus was significantly associated with higher antibi-
otic (including vancomycin) consumption as well. Diabet-
ics used nearly twice as much antibiotics [IRR 1.95 (95%
CI: 1.41–2.54)], while vancomycin use was increased with
36% [IRR 1.36 (95% CI: 1.35–1.37)] compared to patients
without diabetes mellitus.
Molecular epidemiology of staphylococcal isolates
In this study, a total of 407 different S. aureus isolates
were cultured, consisting of 44 genotypically (PFGE)
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distinct strains. During follow-up, 16 of the 20 persistent
carriers remained persistently colonized with the same
resident S. aureus strain as found during the initial
screening phase. In four persistent carriers there was
a change in colonizing S. aureus strain during follow-
up. These changes were all related to antecedent anti-
staphylococcal antibiotic treatment for S. aureus exit site
infection or peritonitis. In two of these patients, exit site
and nasal S. aureus isolates were different by PFGE.
Except for one case of S. aureus peritonitis, all 78 S. aureus
infections in the persistent carriers were of endoge-
nous origin (i.e., with the same genotype strain as had
been found on screening). Four genotypically identical
S. aureus strains were isolated from two patients each,
while all other strains were distinct genotypes.
Only one intermittent carrier patient developed
S. aureus infections: two exit site infections with genotyp-
ically nonidentical strains. Six noncarriers suffered from
S. aureus infections (nine exit site infections and three
peritonitis episodes) during follow-up. Two of them
turned into a persistent carrier, becoming colonized at
the CPD catheter exit site, as well as in their nose, with
an identical S. aureus strain in each case, causing their
S. aureus infections. Two noncarriers became intermit-
tently colonized at the exit site, but their nasal swab cul-
tures remained negative. The two remaining noncarriers
with S. aureus infections had nasal swab and exit site cul-
tures that were always negative for S. aureus.
All 52 patients had one or more cultures positive for
coagulase-negative staphylococci (CoNS). A total of 407
different CoNS isolates were cultured, consisting of 189
genotypically (PFGE) distinct strains. Per patient, a me-
dian of five genotypically distinct CoNS was isolated from
the nose, exit site, and/or abdominal skin. Results varied
widely per culture and per culture site. Moreover, CoNS
strains involved in CPD peritonitis were different from
those found in the screening and follow-up cultures within
patients. Thus, no CoNS carriage ‘pattern’ could be de-
tected in individual patients. The source of CoNS strains
causing infections was not the patients’ microflora on the
abdominal skin or vestibulum nasi.
Antibiotic resistance
All 407 S. aureus strains isolated were methicillin-
sensitive S. aureus (MSSA); no methicillin-resistant S. au-
reus (MRSA) was cultured in this period in this patient
group.
A total of 135 S. aureus isolates were tested for van-
comycin (intermediate) resistance. These included all 92
isolates associated with CPD related infections and the 43
genotypically distinct ‘colonizing’ strains. None of these
S. aureus isolates was vancomycin intermediately suscep-
tible or resistant.
In contrast to the S. aureus strains, methicillin re-
sistance was demonstrated in 280 (69%), and interme-
diate vancomycin susceptibility (MIC 8 (g/L) was de-
tected in eight (2%) out of all 407 CoNS strains tested.
The eight vancomycin intermediately susceptible CoNS
strains were all genotypically distinct S. epidermidis
strains, and were isolated from five different patients. In
one person, three distinct strains were isolated on differ-
ent time points; in one person, two distinct strains were
isolated on different time points; and in three people,
each one distinct strain was isolated only once. None of
these eight vancomycin intermediately susceptible CoNS
strains was implicated in (CPD related) infection. Four
of the five patients from whom a vancomycin interme-
diately susceptible CoNS strain was isolated were per-
sistent carriers; one patient was an intermittent carrier
(P = 0.066 when comparing persistent carriage with non-
carriage/intermittent carriage).
Antibiotic usage was significantly higher in patients
with a vancomycin intermediately susceptible CoNS
strain than in patients without: 0.19 (95% CI: 0.14−0.27)
versus 0.07 (95% CI: 0.04–0.15) antibiotic courses per
month for all causes [IRR 2.65 (95% CI: 1.82–3.84); P <
0.001]. Also, the presence of a vancomycin intermedi-
ately susceptible CoNS strain was significantly associ-
ated with increased vancomycin consumption: 390 (95%
CI: 388–393) versus 123 (95% CI: 121–125) mg of van-
comycin per month [IRR 3.17 (95%: 3.15–3.20); P <
0.001]. When adjusting for age, sex, diabetes mellitus, and
S. aureus nasal carrier state, carrying a vancomycin inter-
mediately susceptible CoNS strain was still significantly
associated with antibiotic usage [IRR 2.07 (95% CI: 1.37–
3.12)] and vancomycin consumption [IRR 2.53 (95% CI:
2.51–2.55)].
DISCUSSION
In the study presented here, 52 patients on CPD were
followed-up closely for a total of 2260 months. More than
2000 cultures were performed, resulting in the isolation of
407 S. aureus and 407 CoNS strains. All 814 staphylococ-
cal isolates were genotyped using PFGE, and all CoNS
plus 135 S. aureus strains were tested for vancomycin
resistance according to Hiramatsu [48]. This is the first
large-scale study to combine the careful assessment of
S. aureus and CoNS carriage patterns and dynamics with
their clinical impact on CPD related morbidity and mor-
tality.
S. aureus nasal carriage has been found to be a ma-
jor risk factor for infections in CPD patients before,
mainly associated with exit infections but not CPD peri-
tonitis, and the incidence rates found in this study are
comparable with these earlier studies [4, 19–25]. Not
surprisingly, intervention studies consistently demon-
strated a significant reduction in the incidence of exit site
1090 Nouwen et al: Clinical impact of staphylococcal carriage in CPD patients
infections, but not a consistent reduction in the incidence
of CPD-related peritonitis [10, 28–32]. These studies have
led to the widespread use of antimicrobial prophylaxis,
mainly with mupirocin, in CPD patients to prevent S. au-
reus infections, often irrespective of the individual carrier
state.
However, in these studies, only one or two nasal swab
or exit site cultures were used to determine the S. aureus
carrier state (carrier versus noncarrier), and genotyping
techniques were not routinely applied. Given the lack of
accepted definitions for the different S. aureus [35], and
given the fact that precise determination of the S. aureus
nasal carriage state seems relevant [36–41], we earlier
derived and validated a culture rule to adequately de-
termine the true carrier state with the least effort [37]. In
healthy individuals it is possible to predict the carrier state
with only two nasal swab cultures. Since CPD patients
are treated with antibiotics regularly, we anticipated that
two cultures would not be enough, and we extended our
screening to six nasal swab cultures together with geno-
typing all strains isolated. Here we demonstrate that dif-
ferentiation between the noncarrier, intermittent carrier,
and persistent carrier state in CPD patients is feasible
and of clinical importance. Persistent carriage, but not
intermittent carriage, is the major determinant of CPD-
related infections, including CPD peritonitis of all micro-
bial causes and CPD peritonitis by CoNS. Persistent car-
riage is also associated with significantly higher antibiotic
consumption, including vancomycin. Targeting interven-
tions to prevent CPD-related infections is thus possible,
thereby eliminating unnecessary prophylactic and thera-
peutic antibiotic use and resistance development [33]. In-
termittent carriers behave like noncarriers as their risk for
CPD-related infections is equally low (0.04 infections per
patient-months at risk). In our opinion, therefore, neither
intermittent nor noncarriers should be offered antibiotic
prophylaxis for the prevention of S. aureus CPD-related
infections. In contrast, prophylaxis should be reserved
for patients shown to be persistent carriers, since only
they have a high rate of CPD-related infections (0.13 per
patient-months at risk).
Two out of 22 noncarriers became persistent carri-
ers, while two others converted to the intermittent car-
rier state during follow-up. Thus, in a proportion of
CPD patients, colonization with S. aureus is a dynamic
process. Consequently, screening for S. aureus carriage
should not be limited to the start of CPD treatment,
but regular (e.g., once a year) determination of the cur-
rent carrier state should be performed and action taken
accordingly.
Eighty percent of persistent carriers were persistently
colonized with their own resident S. aureus strain dur-
ing follow-up, which is in concordance with earlier stud-
ies [35, 52]. Anti-staphylococcal antibiotic treatment for
S. aureus exit site infection or peritonitis induced a change
in S. aureus genotype. As reported earlier, nearly all
S. aureus infections in persistent carriers were of endoge-
nous origin [3, 53]. In total, 44 distinct S. aureus strains
were identified. In contrast to other S. aureus infections
such as impetigo, no clonal spread of strains was observed
[54]. No significant cross-contamination between patients
occurred, since only four genotypically identical S. au-
reus strains were isolated from two patients each, while
all other strains were patient unique. Whether S. aureus
strains causing CPD-related infections harbor specific vir-
ulence factors necessary for successful colonization and
infection, as was reported in other clinical settings [54–
56], is currently not known, but will need to be the subject
of future research.
The molecular epidemiology of CoNS proved to be ex-
tremely complex and dynamic. CoNS were cultured in all
52 patients, but the great variety and variability of strains
within individual patients and the lack of concordance
between colonizing and infecting strains made it impos-
sible to establish a CoNS carriage ‘pattern.’ In contrast to
other settings, no clonal spread was observed [57]. Thus,
the exact source of CoNS strains causing CPD-related
infections could not be determined.
No vancomycin resistance was detected in our
S. aureus isolates, despite the fact that vancomycin in-
traperitoneally is part of the empiric treatment of CPD
peritonitis together with intraperitoneal ceftazidime.
However, antibiotic treatment is adjusted according to
culture results within 72 hours. Since the prevalence
of methicillin-resistant S. aureus (MRSA) is lower than
0.1% in our hospital (including our CPD population),
vancomycin is nearly always changed to flucloxacilline in
the case of S. aureus peritonitis. Only peritonitis by CoNS
has to be treated with vancomycin intraperitoneally since
about 70% of the CoNS strains are methicillin resistant.
Exit and tunnel infections by S. aureus are treated with
flucloxacilline or clindamycine orally, since there is no
need for vancomycin therapy.
However, among the 407 genotypically highly diverse
(189 different genotypes) CoNS strains collected, eight
(2%) demonstrated intermediate susceptibility to van-
comycin. On a strain level, this rate is comparable to the
rate found in a survey of hospital wide CoNS blood cul-
ture isolates in 1991 and 1997 [58]. But more importantly,
this implies that on a patient level, five out of 52 (or 9.6%)
were colonized at least once with a vancomycin interme-
diately susceptible CoNS strain between January 1, 1998
and December 31, 2000. In all five patients (four persis-
tent carriers and one intermittent carrier) concerned this
was significantly related to a higher antibiotic (includ-
ing vancomycin) usage compared to the other 47 CPD
patients (P < 0.001). This implies that even in a set-
ting with relative low vancomycin consumption and low
prevalence of MRSA, the CoNS population serves as a
potential reservoir of vancomycin resistance.
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CONCLUSION
We conclude that persistent, and not intermittent, nasal
carriage of S. aureus is the major determinant of CPD-
related (S. aureus) infections, and that persistent carriage
of S. aureus is associated with a higher consumption of
antibiotics, including vancomycin. Accurate determina-
tion of the S. aureus nasal carriage state makes it pos-
sible to better target future prophylactic strategies. Not
only to prevent CPD-related infections, but also to re-
duce antibiotic consumption and the further emergence
of (vancomycin) resistance staphylococci.
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